AGCO and Bosch BASF Smart Farming Announce Joint Development and Commercialization of Smart Spraying Capabilities
6.4.2023 15:30:00 EEST | Business Wire | Press release
AGCO Corporation announced today that together with Bosch BASF Smart Farming it will integrate and commercialize Smart Spraying technology on Fendt Rogator sprayers, and jointly develop additional, new features.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230406005041/en/
Fendt Rogator 665 using the Smart Spraying Solution targeted spraying in a green-on-brown trial application. (Photo: Business Wire)
In May 2021, AGCO and Bosch BASF Smart Farming started the first trials of Bosch BASF Smart Farming’s innovative Smart Spraying Solution, which will deliver optimal herbicide savings without compromising weed control and will enable targeted spraying during day and night-time conditions. In addition to targeted spraying, the system will deliver integrated digital tools to turn the application data into actionable insights and improve yields and efficiency for farmers. Herbicide savings are delivered through sophisticated sensoring, automated sensitivity thresholds, access to Bosch BASF Smart Farming’s pest identification technology, and the use of Fendt Rogator’s robust application platform. AGCO will offer the system in the Americas and Europe starting in 2024.
Farmers will also be able to benefit from customized agronomic recommendations and reliable documentation within the same solution. The system will offer an end-to-end user experience through AGCO on-board and off-board controls and Bosch BASF Smart Farming’s integrated digital platform from xarvio® Digital Farming Solutions, with insights into the data gathered during the application.
Supported crops currently include corn, soy, cotton, canola, sunflower, and sugarbeet, with capabilities for more crops such as small grains being added over time.
“The progress we have made with Bosch BASF Smart Farming in developing a sustainable solution that maintains productivity while improving profitability and delivering clean fields with maximum savings is an excellent example of AGCO’s farmer focus,” said Seth Crawford, Senior Vice President and General Manager, Precision Ag & Digital, AGCO. “We look forward to our further collaboration with Bosch BASF Smart Farming as we work together to bring this solution to farmers and custom applicators around the world.”
“What makes our system unique is the combination of superior precision, digital tools and the agronomic expertise. With a 24/7 application capability, we create exceptional green-on-green and green-on-brown performance. This type of precision agronomics offering is a breakthrough to support farmers with less impact and higher yields,” said Matt Leininger, Managing Director North America, Bosch BASF Smart Farming.
About AGCO
AGCO (NYSE:AGCO) is a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology. AGCO delivers customer value through its differentiated brand portfolio including core brands like Fendt®, GSI®, Massey Ferguson®, Precision Planting® and Valtra®. Powered by Fuse® smart farming solutions, AGCO’s full line of equipment and services help farmers sustainably feed our world. Founded in 1990 and headquartered in Duluth, Georgia, USA, AGCO had net sales of approximately $12.7 billion in 2022. For more information, visit www.AGCOcorp.com. For company news, information, and events, please follow us on Twitter: @AGCOCorp. For financial news on Twitter, please follow the hashtag #AGCOIR.
About Bosch BASF Smart Farming
Bosch BASF Smart Farming – a joint venture of Bosch and BASF – was established in 2021 to combine the best of two worlds: with the agronomic know-how from BASF and hardware expertise from Bosch, we create the farming of tomorrow, today. Combining precision technology, digital tools, and agronomic intelligence, we offer smart farming solutions that really work to make agriculture more productive, profitable, and sustainable. More information at: www.smartfarming.ag
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005041/en/
Contact information
Julie Ulbrich, AGCO | julie.ulbrich@AGCOCorp.com | +1 770-235-2943
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom